Stocks Under Scanner in the Biotech Space -- Achillion Pharma, Kite Pharma, Acorda Therapeutics, and Tesaro

Thursday, July 6, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 6, 2017 /PRNewswire/ --

If you want a Stock Review on ACHN, KITE, ACOR or TSRO then come over to

and sign up for your free customized report today. On Wednesday, July 05, 2017, the NASDAQ Composite ended the trading session at 6,150.86, up 0.67%; the Dow Jones Industrial Average edged 0.01% lower, to finish at 21,478.17;
and the S&P 500 closed at 2,432.54, slightly advancing 0.15%. US markets saw a mixed session as 4 sectors closed in green, 4 sectors finished in red, and 1 sector ended flat for the day. This Thursday, has initiated reports coverage on the following Biotechnology equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Kite Pharma Inc. (NASDAQ: KITE), Acorda Therapeutics Inc. (NASDAQ: ACOR), and Tesaro Inc. (NASDAQ: TSRO). Take a look at the free research reports issued today on for these stocks by signing up at:

Achillion Pharma 

On Wednesday, shares in New Haven, Connecticut headquartered Achillion Pharmaceuticals Inc. recorded a trading volume of 2.99 million shares, which was above their three months average volume of 1.56 million shares. The stock ended at $5.15, jumping 9.11% from the last trading session. The Company's shares have gained 7.29% in the last one month, 30.38% over the previous three months, and 24.70% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 25.07% and 9.54%, respectively. Furthermore, shares of Achillion Pharma, which discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the US and internationally, have a Relative Strength Index (RSI) of 73.26.  Sign up and read the free research report on ACHN at:

Kite Pharma 

Santa Monica, California headquartered Kite Pharma Inc.'s stock finished yesterday's session 1.98% higher at $106.50 with a total trading volume of 880,568 shares. The Company's shares have surged 44.68% in the last one month, 40.32% over the previous three months, and 137.51% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 28.61% and 66.57%, respectively. Furthermore, shares of Kite Pharma, which focuses on the development and commercialization of novel cancer immunotherapy products, have an RSI of 76.55. The complimentary research report on KITE can be downloaded at:

Acorda Therapeutics 

At the close of trading on Wednesday, shares in Ardsley, New York headquartered Acorda Therapeutics Inc. rose 1.99%, ending the day at $20.50. The stock recorded a trading volume of 801,237 shares. The Company's shares have advanced 33.99% in the last one month, 13.57% in the previous three months, and 9.04% since the start of this year. The stock is trading 24.28% and 0.86% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Acorda Therapeutics, which identifies, develops, and commercializes therapies for neurological disorders in the US, have an RSI of 78.00. Register for free on and access the latest report on ACOR at:


Waltham, Massachusetts headquartered Tesaro Inc.'s shares ended the day 1.37% lower at $140.05 with a total trading volume of 866,551 shares. The stock has gained 4.14% on an YTD basis. The Company's shares are trading 1.59% below their 200-day moving average. Additionally, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US, have an RSI of 45.67. Get free access to your research report on TSRO at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store